Zenas BioPharma (ZBIO) Competitors $25.85 -0.69 (-2.60%) As of 10/14/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZBIO vs. LGND, FOLD, CLDX, MNKD, NVAX, BCRX, OPK, DVAX, INVA, and GERNShould you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Geron (GERN). These companies are all part of the "biotechnology" industry. Zenas BioPharma vs. Its Competitors Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Novavax BioCryst Pharmaceuticals OPKO Health Dynavax Technologies Innoviva Geron Zenas BioPharma (NASDAQ:ZBIO) and Ligand Pharmaceuticals (NASDAQ:LGND) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk. Which has preferable valuation and earnings, ZBIO or LGND? Ligand Pharmaceuticals has higher revenue and earnings than Zenas BioPharma. Ligand Pharmaceuticals is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZenas BioPharma$5M217.71-$156.99M-$3.55-7.28Ligand Pharmaceuticals$167.13M21.22-$4.03M-$4.00-45.23 Do institutionals & insiders believe in ZBIO or LGND? 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 16.5% of Zenas BioPharma shares are owned by insiders. Comparatively, 7.0% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is ZBIO or LGND more profitable? Zenas BioPharma has a net margin of 0.00% compared to Ligand Pharmaceuticals' net margin of -40.44%. Ligand Pharmaceuticals' return on equity of -9.21% beat Zenas BioPharma's return on equity.Company Net Margins Return on Equity Return on Assets Zenas BioPharmaN/A -59.21% -50.56% Ligand Pharmaceuticals -40.44%-9.21%-8.09% Do analysts prefer ZBIO or LGND? Zenas BioPharma presently has a consensus price target of $38.33, indicating a potential upside of 48.29%. Ligand Pharmaceuticals has a consensus price target of $176.50, indicating a potential downside of 2.44%. Given Zenas BioPharma's higher probable upside, research analysts clearly believe Zenas BioPharma is more favorable than Ligand Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zenas BioPharma 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Ligand Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media refer more to ZBIO or LGND? In the previous week, Zenas BioPharma had 45 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 55 mentions for Zenas BioPharma and 10 mentions for Ligand Pharmaceuticals. Ligand Pharmaceuticals' average media sentiment score of 0.95 beat Zenas BioPharma's score of 0.67 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zenas BioPharma 14 Very Positive mention(s) 7 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ligand Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryLigand Pharmaceuticals beats Zenas BioPharma on 8 of the 15 factors compared between the two stocks. Get Zenas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.12B$3.36B$6.06B$10.53BDividend YieldN/A2.31%5.73%4.79%P/E Ratio-7.2821.9085.0527.24Price / Sales217.71474.70592.67237.43Price / CashN/A46.9537.5761.53Price / Book3.4610.4312.676.74Net Income-$156.99M-$52.58M$3.32B$276.59M7 Day Performance23.98%0.98%0.50%0.86%1 Month Performance27.78%14.76%9.42%8.17%1 Year PerformanceN/A21.29%79.11%43.66% Zenas BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BioPharma2.2734 of 5 stars$25.85-2.6%$38.33+48.3%N/A$1.12B$5M-7.28N/AInsider TradeAnalyst RevisionLGNDLigand Pharmaceuticals4.034 of 5 stars$183.16+0.3%$176.50-3.6%+74.9%$3.58B$167.13M-45.7980FOLDAmicus Therapeutics4.5213 of 5 stars$8.16flat$15.78+93.4%-22.8%$2.52B$528.29M-67.99480CLDXCelldex Therapeutics2.1451 of 5 stars$26.22-0.6%$46.13+75.9%-12.6%$1.75B$7.02M-8.71150News CoverageAnalyst ForecastMNKDMannKind3.938 of 5 stars$5.65-0.2%$11.17+97.6%-22.0%$1.74B$285.50M51.37400Positive NewsAnalyst ForecastNVAXNovavax4.2463 of 5 stars$9.22+1.5%$14.29+54.9%-29.6%$1.47B$682.16M4.041,990News CoverageBCRXBioCryst Pharmaceuticals4.1932 of 5 stars$6.95-1.0%$16.30+134.5%-13.9%$1.47B$450.71M-38.61530Trending NewsGap DownOPKOPKO Health4.2309 of 5 stars$1.54-2.5%$2.63+70.5%+3.4%$1.25B$713.10M-6.162,997DVAXDynavax Technologies4.5726 of 5 stars$10.14flat$24.33+140.0%-6.0%$1.19B$277.25M-22.04350INVAInnoviva4.8307 of 5 stars$17.20-1.3%$37.60+118.6%-16.2%$1.10B$358.71M55.49100GERNGeron2.5015 of 5 stars$1.29+0.8%$3.79+193.5%-70.0%$816.66M$76.99M-9.9270News Coverage Related Companies and Tools Related Companies LGND Alternatives FOLD Alternatives CLDX Alternatives MNKD Alternatives NVAX Alternatives BCRX Alternatives OPK Alternatives DVAX Alternatives INVA Alternatives GERN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
